Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Bispecific antibodies for non-Hodgkin lymphoma

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, reflects on the use of bispecific antibodies in the treatment of non-Hodgkins lymphoma, including glofitamab and epcoritamab, both CD20xCD3 bispecific antibodies. Furthermore, Dr Hutchings elaborates on the implementation of bispecific antibodies in the treatment regime of non-Hodgkins lymphoma patients and its curative potential for highly refractory patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).